Terminal galactose glycan (Gal-glycan)

Terminal galactose glycans are carbohydrate structures characterized by the presence of a galactose residue at the non-reducing terminus of an oligosaccharide chain (Varki et al., 2017). These glycans serve as essential recognition motifs for various biological receptors, most notably the galectin family and the asialoglycoprotein receptor (ASGPR) (Stockert, 1995). In physiological conditions, they mediate processes such as cell-cell adhesion, immune cell activation, and the clearance of desialylated glycoproteins from the bloodstream (Cummings et al., 2017). In disease states, particularly oncology, the overexpression or altered branching of terminal galactose residues, such as the Thomsen-Friedenreich (TF) antigen, is associated with tumor progression and metastasis (Springer, 1984). Therapeutic interventions often involve small molecule inhibitors or carbohydrate mimetics designed to block galectin-3, which is implicated in fibrosis and cancer (Johannes et al., 2018). Additionally, terminal galactose and its derivative N-acetylgalactosamine (GalNAc) are extensively used as targeting moieties in conjugate chemistry to deliver siRNA or antisense oligonucleotides specifically to hepatocytes via ASGPR (Springer et al., 2018). The specificity of these interactions is highly dependent on the linkage type and the "cluster effect," where multiple glycan units increase binding affinity (D'Souza & Devarajan, 2015). Consequently, terminal galactose glycans represent both a pathological biomarker and a versatile tool for precision medicine.

Other names

Terminal beta-galactosideGalactose-terminated glycanAsialoglycanThomsen-Friedenreich antigenNon-reducing terminal galactose

Inhibition of galectin-mediated signaling or utilization of asialoglycoprotein receptor (ASGPR) mediated endocytosis for targeted drug delivery.